CoChat

Seladelpar improved measures of pruritus, sleep, and fatigue and decreased serum bile acids in patients with primary biliary cholangitis

Open access
Kremer, Andreas E., Mayo, Marlyn J., Hirschfield, Gideon, Levy, Cynthia, Bowlus, Christopher L., Jones, David E., Steinberg, Alexandra, McWherter, Charles A., Choi, Yun‐Jung · 2022 · Liver International
Cited by 89

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Abstract

Background & Aims: Primary biliary cholangitis (PBC) can result in life‐altering cholestatic pruritus and fatigue, but treatment options are limited. Seladelpar, a peroxisome proliferator‐activated receptor‐delta (PPARδ) agonist, has demonstrated potent anti‐cholestatic effects in clinical studies. This open‐label, uncontrolled phase 2 study in PBC patients evaluated the effects of 1‐year of seladelpar treatment on measures of pruritus and quality of life. Methods: Self‐reported experiences of 101 PBC patients were collected at baseline and after 1 year of seladelpar treatment using the pruritus visual analog scale (VAS), 5D‐itch scale, and PBC‐40 questionnaires along with bile acid profiles. Results: In patients with moderate–to‐severe pruritus, substantial improvement in pruritus was seen in 58% and 93% of patients in 5/10 mg and 10 mg treatment groups, respectively. After 1 year, patients reporting improvement substantially outnumbered those who worsened in the total 5‐D itch (including individual domains) and PBC‐40 (itch and fatigue domains) questionnaires. Improvement in sleep disturbance at 1‐year was reported in 81% (5/10 mg) and 78% (10 mg) of the patients with baseline itch‐related sleep disturbance by 5‐D itch score with similar results using the PBC‐40 sleep questionnaire. Seladelpar‐treated patients had significant reductions of 46% (5/10 mg) and 31% (10 mg) in the serum bile acid precursor C4 and reductions of up to 38% in serum bile acids. Conclusions: Seladelpar treatment for 1 year led to consistent improvement in both symptom burden and biochemical response, suggesting its potential as a single agent to address two key unmet needs in PBC patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/liv.15039

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 14 references

Research works printed but not linked: 28

  1. Galoosian A, 2020, Clinical updates in primary biliary cholangitis: trends, epidemiology, diagnostics, and new therapeutic approaches, J Clin Transl Hepatol, 8, 49
  2. 10.1002/cld.867 · DOI
  3. 10.1053/bega.2000.0109 · DOI
  4. 10.1002/hep.29698 · DOI
  5. 10.1007/s11901-020-00517-x · DOI
  6. 10.1016/j.amjmed.2017.01.037 · DOI
  7. 10.1136/flgastro-2015-100618 · DOI · Paper page
  8. 10.1007/s10620-019-05786-1 · DOI
  9. 10.1007/s11901-019-00458-0 · DOI
  10. 10.1111/liv.13919 · DOI · Paper page
  11. 10.1016/j.jhep.2013.02.019 · DOI · Paper page
  12. 10.1016/S2468-1253(17)30246-7 · DOI · Paper page
  13. 10.1016/S0168-8278(20)31411-2 · doi:10.1016/s0168-8278(20)31411-2
  14. 10.1111/j.1365-2133.2009.09586.x · DOI · Paper page
  15. 10.1136/gut.2005.065862 · DOI · Paper page
  16. 10.2340/00015555-1265 · DOI · Paper page
  17. 10.2340/00015555-2433 · DOI
  18. 10.1111/j.1572-0241.2006.00423.x · DOI
  19. Bowlus C, 2018, Efficacy and safety of seladelpar, a selective peroxisome proliferator activated receptor delta agonist, in primary biliary cholangitis: 52‐week analysis of an ongoing international, randomized, dose ranging phase 2 study, Hepatology, 68, 1445A
  20. Boudes P, 2018, Seladelpar’s mechanism of action as a potential treatment for primary biliary cholangitis and non‐alcoholic steatohepatitis, J Hepatol, 68, S235, 10.1016/S0168-8278(18)30688-3 · doi:10.1016/s0168-8278(18)30688-3
  21. 10.1210/jc.2011-1061 · DOI · Paper page
  22. 10.1007/s11894-019-0713-6 · DOI
  23. 10.1002/hep.21271 · DOI · Paper page
  24. 10.1111/apt.13449 · DOI · Paper page
  25. 10.1073/pnas.1903316116 · DOI · Paper page
  26. 10.7554/eLife.48431 · DOI · Paper page
  27. Wolf K, 2019, Bile salt subspecies activate MRGX4 expressed on sensory neurons and cause itching in humans, Hepatology, 70, 769A
  28. 10.1038/srep30847 · DOI

Cited by

See all 89

Metadata

Authors
Kremer, A. E., Mayo, M. J., Hirschfield, G., Levy, C., Bowlus, C. L., Jones, D. E., Steinberg, A., McWherter, C. A., & Choi, Y.
Venue
Liver International
Publisher
Wiley
Published
2021-08-26
Volume
42
Issue
1
Pages
112-123
ISSN
  • 0106-9543 (ISSN-L)
  • 1478-3223
  • 1478-3231
OpenAlex
W3193674176
Cited by
89
References
14
FWCI
6.09
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Seladelpar improved measures of pruritus, sleep, and fatigue and decreased serum bile acids in patients with primary biliary cholangitis. https://app.cochat.ai/papers/10.1111/liv.15039
The paper
Kremer, A. E., Mayo, M. J., Hirschfield, G., Levy, C., Bowlus, C. L., Jones, D. E., Steinberg, A., McWherter, C. A., & Choi, Y. (2022). Seladelpar improved measures of pruritus, sleep, and fatigue and decreased serum bile acids in patients with primary biliary cholangitis. Liver International. https://doi.org/10.1111/liv.15039

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.